Thursday 12 October is RARESummit - the bi-annual rare disease event organised by @camraredisease . Really looking forward to hearing from policy-makers, researchers, patient voices and innovators. If you can’t be there you can follow #RAREsummit23
It’s great news that there’s another treatment for #Fabry. However in what context is ‘a small co-pay’ applicable on the #NHS?
Elfabrio was approved in the U.K. https://t.co/Ge7C6g7dqC
There are 42 integrated care systems across England, covering populations of around 500,000 to 3 million people. But why are they needed, and how do they work? Read our ICS explainer to find out. https://t.co/tupBH4TBus
'The New Opportunity to Help Rare Disease Patients'🧡
The article from @medcitynews discusses investment in rare diseases and how global spending on rare diseases is estimated to reach $260 billion by the end of 2025.
Read more here:
https://t.co/7Xz2j1jSgJ
Calling all healthcare professions – why not begin your genomics knowledge journey today with a short course? This Genomics 101 module introduces the testing process, including why, when and how genomic testing is done: https://t.co/F8seCeV0rv
Looking for abnormal, clumped features called mulberry bodies in a person's urine may help in the diagnosis of Fabry disease, a study found. https://t.co/XHCtvRMbSe
Blood levels of periostin, a protein associated with kidney injury, may be a valuable marker for kidney damage in Fabry disease, a study says. https://t.co/rmNQs0eQrC
ST-920, a potential gene therapy for Fabry disease, has been granted fast track designation by the U.S. Food and Drug Administration. https://t.co/wD6bmHilvm
2023 Orphan Drugs: PDUFA Dates and FDA Approvals
Click on the link below👇 to view the list of important regulatory dates for all orphan drugs for 2023.
https://t.co/43UC64oZKm
#rarediseases#drugapprovals